» Articles » PMID: 36457563

The Prevalence, Comorbidities, Influencing Factors, and Identifying Factors of Non-obese Fatty Liver Disease

Overview
Specialty General Medicine
Date 2022 Dec 2
PMID 36457563
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment.

Materials And Methods: Firstly, to screen data obtained from the physical examinations of individuals conducted in the Second Affiliated Hospital of Xi'an Jiaotong University in 2021, subjects with complete data of abdominal ultrasonography, body mass index, age and sex were selected to analyze the prevalence of fatty liver disease and non-obese fatty liver disease. Secondly, to screen non-obese subjects who had data for triglycerides, fasting blood glucose, and so on, to analyze the complications, influencing factors, and identifying factors of non-obese fatty liver disease.

Results: The prevalence of fatty liver disease was 27.8% (18,416/66,221), including 33.9% (11,921/35,131) in males and 20.9% (6,495/31,090) in females, revealing that the prevalence was significantly higher in males than in females ( < 0.001). There were 40,673 non-obese subjects screened in total, and the prevalence of non-obese fatty liver disease was 13.0% (5,307/40,673). The prevalence of non-obese fatty liver disease was 13.3% (2,208/16,572) in males and 12.9% (3,099/24,101) in females; the difference was not statistically significant ( = 0.17). The serum triglycerides level was elevated in 54.2% of subjects with non-obese fatty liver disease, and this was the most common abnormal metabolic index accompanying the disease. Logistic regression analysis showed that gender, age, body mass index, blood pressure, alanine aminotransferase, aspartate aminotransferase, fasting blood glucose, triglycerides, total cholesterol, and serum uric acid were independent risk factors for non-obese fatty liver disease ( < 0.001). For triglycerides, the area under the receiver operating characteristic curve in predicting non-obese fatty liver disease was the greatest (0.806).

Conclusion: The prevalence of fatty liver disease and non-obese fatty liver disease determined by the physical examination of individuals was high, and the triglycerides is likely to be useful for the extensive screening of non-obese fatty liver disease.

Citing Articles

Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China.

Zhu R, Xu C, Jiang S, Xia J, Wu B, Zhang S Eur J Med Res. 2025; 30(1):137.

PMID: 40001266 PMC: 11863909. DOI: 10.1186/s40001-025-02373-1.


Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications.

Tidwell J, Wu G J Clin Transl Hepatol. 2024; 12(1):70-78.

PMID: 38250459 PMC: 10794266. DOI: 10.14218/JCTH.2023.00252.


SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.

Li X, Du Y, Xue C, Kang X, Sun C, Peng H Int J Mol Sci. 2023; 24(10).

PMID: 37240315 PMC: 10219207. DOI: 10.3390/ijms24108970.

References
1.
Ha Y, Seo N, Shim J, Kim S, Park J, Han S . Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015; 30(11):1666-72. DOI: 10.1111/jgh.12996. View

2.
Ahadi M, Molooghi K, Masoudifar N, Namdar A, Vossoughinia H, Farzanehfar M . A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2020; 36(6):1497-1507. DOI: 10.1111/jgh.15353. View

3.
Kuchay M, Martinez-Montoro J, Choudhary N, Fernandez-Garcia J, Ramos-Molina B . Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines. 2021; 9(10). PMC: 8533092. DOI: 10.3390/biomedicines9101346. View

4.
Fatima K, Moeed A, Waqar E, Atif A, Kamran A, Rizvi H . Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021; 46(4):101816. DOI: 10.1016/j.clinre.2021.101816. View

5.
Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa M . Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord. 2021; 22(2):351-366. PMC: 8893229. DOI: 10.1007/s11154-020-09621-1. View